| Dr Raymond G Overstreet, MD | |
|
1001 Main St, Columbus, MS 39701-4751 | |
| (662) 328-9225 | |
| (662) 328-4735 |
| Full Name | Dr Raymond G Overstreet |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 43 Years |
| Location | 1001 Main St, Columbus, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447350541 | NPI | - | NPPES |
| 0014986 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 10923 (Mississippi) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Boa Vida Hospital Of Aberdeen Ms Llc | 0244505840 | 43 |
| Region Seven Mental Health Intellectual Disabilities Comm | 3072531953 | 8 |
News Archive
Over the years, advances in treatment have improved the chances of survival for young patients with cancer. But long-term survivors need to be aware of cancer treatments that may place them at increased risk of heart disease later in life.
Disease-causing bacteria stink - literally - and the odor released by some of the nastiest microbes has become the basis for a faster and simpler new way to diagnose blood infections and finger the specific microbe, scientists reported here today at the 246th National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society.
ChemGenex Pharmaceuticals announces that the U.S. Food and Drug Administration's Office of Oncology Drug Products has issued a complete response letter regarding the new drug application for OMAPRO for the treatment of adults with chronic myeloid leukemia who have failed prior therapy with imatinib and have the Bcr-Abl T315I mutation.
Formation of new blood vessels, a process also known as angiogenesis, is one of the major clinical challenges in wound healing and tissue implants. To address this issue, researchers from Texas A&M University have developed a clay-based platform to deliver therapeutic proteins to the body to assist with the formation of blood vessels.
› Verified 5 days ago
| Entity Name | Region Seven Mental Health Intellectual Disabilities Comm |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700894730 PECOS PAC ID: 3072531953 Enrollment ID: O20051109000565 |
News Archive
Over the years, advances in treatment have improved the chances of survival for young patients with cancer. But long-term survivors need to be aware of cancer treatments that may place them at increased risk of heart disease later in life.
Disease-causing bacteria stink - literally - and the odor released by some of the nastiest microbes has become the basis for a faster and simpler new way to diagnose blood infections and finger the specific microbe, scientists reported here today at the 246th National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society.
ChemGenex Pharmaceuticals announces that the U.S. Food and Drug Administration's Office of Oncology Drug Products has issued a complete response letter regarding the new drug application for OMAPRO for the treatment of adults with chronic myeloid leukemia who have failed prior therapy with imatinib and have the Bcr-Abl T315I mutation.
Formation of new blood vessels, a process also known as angiogenesis, is one of the major clinical challenges in wound healing and tissue implants. To address this issue, researchers from Texas A&M University have developed a clay-based platform to deliver therapeutic proteins to the body to assist with the formation of blood vessels.
› Verified 5 days ago
| Entity Name | Boa Vida Hospital Of Aberdeen Ms Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710405741 PECOS PAC ID: 0244505840 Enrollment ID: O20171128003460 |
News Archive
Over the years, advances in treatment have improved the chances of survival for young patients with cancer. But long-term survivors need to be aware of cancer treatments that may place them at increased risk of heart disease later in life.
Disease-causing bacteria stink - literally - and the odor released by some of the nastiest microbes has become the basis for a faster and simpler new way to diagnose blood infections and finger the specific microbe, scientists reported here today at the 246th National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society.
ChemGenex Pharmaceuticals announces that the U.S. Food and Drug Administration's Office of Oncology Drug Products has issued a complete response letter regarding the new drug application for OMAPRO for the treatment of adults with chronic myeloid leukemia who have failed prior therapy with imatinib and have the Bcr-Abl T315I mutation.
Formation of new blood vessels, a process also known as angiogenesis, is one of the major clinical challenges in wound healing and tissue implants. To address this issue, researchers from Texas A&M University have developed a clay-based platform to deliver therapeutic proteins to the body to assist with the formation of blood vessels.
› Verified 5 days ago
| Entity Name | Tmk Enterprises |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184251795 PECOS PAC ID: 1254760341 Enrollment ID: O20200413000974 |
News Archive
Over the years, advances in treatment have improved the chances of survival for young patients with cancer. But long-term survivors need to be aware of cancer treatments that may place them at increased risk of heart disease later in life.
Disease-causing bacteria stink - literally - and the odor released by some of the nastiest microbes has become the basis for a faster and simpler new way to diagnose blood infections and finger the specific microbe, scientists reported here today at the 246th National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society.
ChemGenex Pharmaceuticals announces that the U.S. Food and Drug Administration's Office of Oncology Drug Products has issued a complete response letter regarding the new drug application for OMAPRO for the treatment of adults with chronic myeloid leukemia who have failed prior therapy with imatinib and have the Bcr-Abl T315I mutation.
Formation of new blood vessels, a process also known as angiogenesis, is one of the major clinical challenges in wound healing and tissue implants. To address this issue, researchers from Texas A&M University have developed a clay-based platform to deliver therapeutic proteins to the body to assist with the formation of blood vessels.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Raymond G Overstreet, MD 1032 State Hwy 50 W, P.o. Box 1188, West Point, MS 39773 Ph: (662) 524-4347 | Dr Raymond G Overstreet, MD 1001 Main St, Columbus, MS 39701-4751 Ph: (662) 328-9225 |
News Archive
Over the years, advances in treatment have improved the chances of survival for young patients with cancer. But long-term survivors need to be aware of cancer treatments that may place them at increased risk of heart disease later in life.
Disease-causing bacteria stink - literally - and the odor released by some of the nastiest microbes has become the basis for a faster and simpler new way to diagnose blood infections and finger the specific microbe, scientists reported here today at the 246th National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society.
ChemGenex Pharmaceuticals announces that the U.S. Food and Drug Administration's Office of Oncology Drug Products has issued a complete response letter regarding the new drug application for OMAPRO for the treatment of adults with chronic myeloid leukemia who have failed prior therapy with imatinib and have the Bcr-Abl T315I mutation.
Formation of new blood vessels, a process also known as angiogenesis, is one of the major clinical challenges in wound healing and tissue implants. To address this issue, researchers from Texas A&M University have developed a clay-based platform to deliver therapeutic proteins to the body to assist with the formation of blood vessels.
› Verified 5 days ago
Dr. Richard Joseph Levitre, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 14th Medical Group 201 Independence Drive, Columbus, MS 39710 Phone: 662-434-2273 | |
Saleem Akber Ali, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2520 Fifth Street North, Columbus, MS 39705 Phone: 662-244-2561 Fax: 662-244-2575 |